Apexian Pharmaceuticals preclinical studies with APX3330 shuts down inflammatory signaling in leukemia

Indianapolis, IN – December 20, 2018 – An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia.  Apexian Pharmaceuticals’ latest studies in collaboration with Indiana University’s Simon Cancer Center investigator Dr. Reuben Kapur show promise for halting that transformation. These results, published December 6, 2018, in Cell Stem Cell, explain how … Read more…

Apexian Pharmaceuticals presents findings at ASH meeting demonstrating APX3330 impact on inflammation and leukemia in preclinical models

Indianapolis, IN – December 12, 2018 – Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Genetic mutations by themselves are rarely enough to flip the switch. Inflammation also plays a role. But, until now, the question of “how” remained unanswered. Apexian Chief Science Officer Mark Kelley, PhD, and his colleagues presented their findings at the American Society … Read more…